Plasma Fractionation Market Trends

ID: MRFR/HC/5928-CR

200 Pages

Rahul Gotadki

July 2025

Plasma Fractionation Market Research Report: Size, Share, Trend Analysis By Applications (Neurology, Hematology, General Medicine, Immunology), By Product Type (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors), By End Users (Hospitals, Ambulatory Surgical Centers, Blood Banks, Pharmaceutical Companies), By Technology (Centrifugation, Chromatography, Precipitation, Filtration) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Plasma Fractionation Market

The heavy-duty vehicle rental market is presently experiencing considerable shifts and traits that can be shaping its landscape. One extremely good fashion is the growing demand for green and sustainable alternatives within this area. With an accelerated worldwide consciousness of environmental conservation and lowering carbon footprints, companies are looking for heavy-duty motors that adhere to stricter emission requirements. This has led to the creation of electric and hybrid alternatives in the heavy-duty vehicle rental marketplace, presenting companies with the opportunity to align their operations with sustainable practices. Another noteworthy marketplace fashion is the upward push of digitalization and era integration in heavy-duty vehicle rentals. The creation of superior telematics and fleet management systems has enabled condo companies to optimize their operations, enhance car performance, and provide real-time monitoring for their customers. This now not only improves performance but also contributes to a greater seamless condo experience for groups relying on heavy-duty vehicles for their operations. The international economic landscape is also influencing marketplace trends in heavy-duty vehicle rentals. As economies get over various disruptions, there is an observable boom in creation and infrastructure tasks, contributing to a heightened demand for heavy-duty motors. This uptick in production activities, coupled with the want for efficient transportation of products, is using the demand for heavy-obligation motors, therefore influencing the boom of the rental market. Moreover, regulatory modifications and compliance requirements are shaping the heavy-duty vehicle rental market. Governments international are implementing stricter guidelines on emissions, protection, and other components of vehicle operation. Rental businesses are adapting to these adjustments by updating their fleets to satisfy brand-new standards, ensuring compliance with policies, and supplying customers with motors that align with ultra-modern enterprise requirements. In terms of geographical trends, emerging markets are getting an increasing number of extensive gamers inside the heavy-duty vehicle rental enterprise. As organizations extend their operations globally, the demand for dependable heavy-duty vehicle rental services in emerging economies is at an upward push. This has led to the established order of new apartment groups in these areas, catering to the growing desires of agencies running in various sectors. In conclusion, the heavy-duty vehicle rental marketplace presents dynamic process adjustments driven by environmental concerns, technological advancements, consumer possibilities, economic factors, regulatory shifts, and the globalization of organizations. As the industry continues to adapt, condominium corporations that adapt to these traits and offer progressive answers are probably to thrive in this competitive marketplace. Whether it's embracing sustainability, integrating modern-day generations, or presenting bendy rental options, the heavy-duty vehicle rental area is poised for persistent transformation in the coming years.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the current valuation of the Plasma Fractionation Market?

As of 2024, the Plasma Fractionation Market was valued at 31.82 USD Billion.

What is the projected market size for the Plasma Fractionation Market by 2035?

The market is projected to reach 64.22 USD Billion by 2035.

What is the expected CAGR for the Plasma Fractionation Market during the forecast period 2025 - 2035?

The expected CAGR for the Plasma Fractionation Market during 2025 - 2035 is 6.59%.

Which application segment is anticipated to have the highest valuation in 2035?

The General Medicine application segment is projected to reach between 10.0 and 20.0 USD Billion by 2035.

What are the key product types in the Plasma Fractionation Market?

Key product types include Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors.

Which end user segment is expected to dominate the market by 2035?

The Hospitals end user segment is anticipated to grow to between 12.0 and 25.0 USD Billion by 2035.

What technologies are utilized in the Plasma Fractionation process?

Technologies used include Centrifugation, Chromatography, Precipitation, and Filtration.

Who are the leading companies in the Plasma Fractionation Market?

Key players include Grifols, CSL Behring, Takeda Pharmaceutical Company Limited, and Octapharma.

What is the projected valuation for the Immunoglobulin product type by 2035?

The Immunoglobulin product type is expected to reach between 12.0 and 25.0 USD Billion by 2035.

How does the Plasma Fractionation Market's growth compare across different segments?

The market shows varied growth across segments, with Hematology and Immunology also projected to see substantial increases.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future analysis, the Plasma Fractionation Market Size was estimated at 31.82 USD Billion in 2024. The Plasma Fractionation industry is projected to grow from 33.92 USD Billion in 2025 to 64.22 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.5% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Plasma Fractionation Market is poised for robust growth driven by technological advancements and increasing demand for therapies.

Technological advancements are enhancing the efficiency and yield of plasma fractionation processes. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region in this sector. The immunology segment dominates the market, whereas the hematology segment is witnessing rapid growth. Key market drivers include the rising incidence of hematological disorders and growing awareness of immunoglobulin therapies.

Plasma Fractionation Market

CAGR

6.59%

Market Size & Forecast

2024 Market Size	31.82 (USD Billion)
2035 Market Size	64.22 (USD Billion)
CAGR (2025 - 2035)	6.59%
Largest Regional Market Share in 2024	North America

Major Players

Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), <a href="https://www.octapharma.com/news/corporate-news/2025/octapharma-appointed-sole-fractionator-for-uk-s-plasma-programme">Octapharma</a> (CH), Kedrion S.p.A. (IT), Biotest AG (DE), LFB Group (FR), Hualan Biological Engineering Inc. (CN)

Market Trends

The Plasma Fractionation Market is currently experiencing a dynamic evolution, driven by advancements in technology and increasing demand for immunoglobulins and clotting factors. This sector plays a crucial role in the healthcare landscape, particularly in the treatment of various diseases and conditions, including immune deficiencies and bleeding disorders. The growing awareness of the therapeutic benefits of plasma-derived products, including plasma fractionators, is fostering a robust market environment. Furthermore, the rise in research and development activities is likely to enhance product offerings, thereby expanding the market's potential. In addition, regulatory frameworks are becoming more stringent, which may influence the operational strategies of companies within the Plasma Fractionation Market. Organizations are adapting to these changes by investing in compliance and quality assurance measures. The global landscape is also witnessing a shift towards more sustainable practices, as stakeholders recognize the importance of ethical sourcing and environmental responsibility. This multifaceted approach suggests that the Plasma Fractionation Market is poised for continued growth, with opportunities for innovation and collaboration across various sectors.

Technological Advancements

The Plasma Fractionation Market is witnessing a surge in technological innovations that enhance the efficiency and yield of plasma processing. Automation and advanced separation techniques are being integrated into production processes, which may lead to improved product quality and reduced operational costs. These advancements not only streamline plasma fractionator manufacturing but also ensure compliance with regulatory standards, thereby fostering market growth.

Rising Demand for Plasma-Derived Therapies

There is an increasing global demand for plasma-derived therapies, particularly immunoglobulins and clotting factors. This trend is driven by a growing prevalence of chronic diseases and a heightened focus on personalized medicine. As healthcare providers seek effective treatment options using plasma fractionators, the Plasma Fractionation Market is likely to expand, catering to the needs of diverse patient populations.

Focus on Sustainability

Sustainability is becoming a pivotal concern within the Plasma Fractionation Market. Companies are increasingly adopting eco-friendly practices and ethical sourcing of plasma. This shift not only addresses environmental challenges but also aligns with consumer expectations for responsible production. As stakeholders prioritize sustainability, the market may see a transformation in operational strategies and product offerings.

Plasma Fractionation Market Market Drivers

Expansion of Healthcare Infrastructure

The ongoing expansion of healthcare infrastructure in various regions is significantly influencing the Plasma Fractionation Market. As countries invest in improving their healthcare systems, the availability of advanced medical facilities and technologies is increasing. This expansion facilitates better access to plasma-derived therapies, which are essential for treating a range of medical conditions. For instance, the establishment of specialized treatment centers and blood banks enhances the collection and processing of plasma, thereby supporting the growth of the Plasma Fractionation Market. Moreover, the integration of state-of-the-art technologies in healthcare facilities is likely to improve the efficiency of plasma fractionation processes. As a result, the market may witness a surge in demand for plasma-derived products, driven by the enhanced capabilities of healthcare providers to deliver effective treatments.

Rising Demand for Personalized Medicine

The growing trend towards personalized medicine is significantly impacting the Plasma Fractionation Market. As healthcare shifts towards tailored treatment approaches, the demand for plasma-derived therapies that can be customized to individual patient needs is likely to increase. Personalized medicine aims to optimize therapeutic outcomes by considering genetic, environmental, and lifestyle factors. This approach aligns well with the capabilities of plasma fractionation, which allows for the development of specific products targeting unique patient profiles. Recent studies suggest that personalized therapies can lead to improved patient outcomes and reduced healthcare costs, further driving interest in plasma-derived products. Consequently, the Plasma Fractionation Market may experience a surge in demand as healthcare providers and patients seek more effective and individualized treatment options.

Growing Awareness of Immunoglobulin Therapies

The increasing awareness regarding the benefits of immunoglobulin therapies is a notable driver for the Plasma Fractionation Market. Immunoglobulins, derived from human plasma, play a vital role in treating various immunodeficiency disorders and autoimmune diseases. As healthcare professionals and patients become more informed about these therapies, the demand for immunoglobulin products is likely to rise. Recent data indicates that the immunoglobulin market is projected to reach approximately USD 20 billion by 2026, reflecting a robust growth trajectory. This trend suggests that the Plasma Fractionation Market will experience heightened interest and investment as stakeholders recognize the therapeutic potential of immunoglobulins. Additionally, the increasing number of clinical trials and research initiatives focused on immunoglobulin therapies may further stimulate market growth, as new applications and formulations are explored.

Regulatory Support for Plasma-Derived Products

Regulatory support for plasma-derived products is emerging as a significant driver for the Plasma Fractionation Market. Governments and regulatory bodies are increasingly recognizing the importance of plasma therapies in treating various medical conditions. This recognition has led to the establishment of favorable policies and guidelines that facilitate the approval and commercialization of plasma-derived products. For instance, streamlined regulatory processes can expedite the introduction of new therapies into the market, thereby enhancing patient access to essential treatments. Furthermore, the emphasis on safety and efficacy in the approval process is likely to bolster consumer confidence in plasma-derived products. As a result, the Plasma Fractionation Market may benefit from increased investment and innovation, as companies seek to develop new and improved therapies that meet regulatory standards.

Increasing Incidence of Hematological Disorders

The rising prevalence of hematological disorders, such as hemophilia and multiple myeloma, is a crucial driver for the Plasma Fractionation Market. As these conditions require specific plasma-derived products for treatment, the demand for plasma fractionation is expected to grow. According to recent estimates, the incidence of hemophilia is approximately 1 in 5,000 male births, indicating a substantial patient population reliant on plasma-derived therapies. This trend suggests that healthcare providers are increasingly focusing on developing effective treatment options, thereby propelling the Plasma Fractionation Market forward. Furthermore, advancements in diagnostic techniques are likely to enhance early detection, leading to timely interventions and increased demand for plasma products. Consequently, the market is poised for growth as healthcare systems adapt to the rising burden of hematological disorders.

Market Segment Insights

Plasma Fractionation Market Application Insights

The Plasma Fractionation Market is witnessing substantial growth across various applications, reflecting its significance in the healthcare industry, particularly in the fields of Neurology, Hematology, General Medicine, and Immunology. In 2024, the market is projected to be valued at 23.66 USD Billion, with applications playing a crucial role in driving this growth. Among the applications, Hematology and General Medicine are significant contributors, demonstrating majority holdings in market value.

Hematology is anticipated to reach 6.8 USD Billion in 2024 before growing to 10.5 USD Billion by 2035, indicating the demand for plasma-derived products in the management of blood disorders. General Medicine is also expected to show considerable growth, starting at 8.9 USD Billion in 2024 and increasing to 13.8 USD Billion by 2035.

This reflects the essential role plasma fractionation plant plays in treating various conditions, from immune disorders to infections.On the other hand, Neurology is another pivotal application, valued at 5.5 USD Billion in 2024, with expectations to rise to 8.7 USD Billion by 2035.

Plasma Fractionation Market Product Type Insights

The Plasma Fractionation Market is experiencing significant growth, projected to reach a market value of 23.66 USD Billion in 2024, driven by the increasing demand for plasma-derived therapies across various applications. The market is segmented into several product types, with Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors being the key categories.

Immunoglobulin holds a major share of the market due to its essential role in treating immunodeficiencies and autoimmune disorders. <a href="https://www.marketresearchfuture.com/reports/albumin-market-7442">Albumin</a>, with its critical applications in managing shock and burns, is also a dominant product type, demonstrating its importance in medical treatments globally.Coagulation Factors are significant in the hemophilia treatment landscape, facilitating effective management of bleeding disorders. Protease Inhibitors

play a vital role in therapeutic applications, particularly in antiviral and anti-inflammatory treatments. The growth in this market segment is propelled by rising healthcare investments and technological advancements, bolstering the Plasma Fractionation Market data and statistics. However, the market faces challenges, including regulatory hurdles and fluctuating plasma supply, which may impact production and distribution.

Plasma Fractionation Market End User Insights

The Plasma Fractionation Market is set to experience significant growth with various end users playing crucial roles in shaping its landscape. By 2024, the market is expected to be valued at approximately 23.66 billion USD, reflecting the increasing reliance on plasma-derived therapeutics in healthcare.

Hospitals serve as key players in this segment, leveraging plasma fractionation products for patients requiring immunoglobulins and clotting factor treatments, thus enhancing patient recovery and care standards.

Ambulatory Surgical Centers, known for their emphasis on outpatient procedures, also benefit from the availability of plasma therapies, ensuring effective treatments while optimizing operational efficiencies.Blood Banks are fundamental to this market as they are responsible for collecting and processing plasma, ensuring a steady supply for various applications in medicine.

Plasma Fractionation Market Technology Insights

The Plasma Fractionation Market within the Technology segment is a crucial area, expected to reach a valuation of 23.66 billion USD by 2024. This market encompasses various techniques essential for the separation and purification of plasma proteins, with methods such as Centrifugation, Chromatography, Precipitation, and Filtration playing significant roles.

Centrifugation is widely utilized for its efficiency in separating components based on density, while Chromatography enhances the purity of plasma derivatives, making it a preferred choice in Research and Development.Precipitation offers a cost-effective solution for isolating proteins, and Filtration provides a reliable method for removing impurities. These techniques not only contribute to the efficacy of plasma treatments but also drive advancements in therapeutic applications worldwide.

The market growth stems from an increasing demand for clotting factor concentrates and immunoglobulins, facilitating improved patient outcomes and addressing critical health challenges globally. As a result, the exploration of innovative technologies in this segment promises to elevate the standards of healthcare solutions derived from plasma fractionation plants.

Get more detailed insights about Plasma Fractionation Market Research Report – Global Forecast till 2035

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for plasma fractionation, holding approximately 45% of the global share. The region benefits from advanced healthcare infrastructure, high demand for immunoglobulins, and supportive regulatory frameworks. The increasing prevalence of chronic diseases and the aging population are significant growth drivers. Regulatory bodies like the FDA ensure stringent quality standards, further boosting market confidence. The United States is the leading country in this region, with major players such as Grifols and CSL Behring establishing a strong presence. Canada also contributes significantly, focusing on research and development in biopharmaceuticals. The competitive landscape is characterized by innovation and strategic partnerships among key players, enhancing product offerings and market reach.

Europe : Emerging Market with Growth Potential

Europe is the second-largest market for plasma fractionation plants, accounting for around 30% of the global market share. The region is witnessing increased demand for plasma-derived therapies, driven by rising healthcare expenditures and a growing patient population. Regulatory support from the European Medicines Agency (EMA) is pivotal in ensuring product safety and efficacy, which fosters market growth and innovation. Germany, France, and the UK are the leading countries in this market, with significant contributions from companies like Octapharma and LFB Group. The competitive landscape is evolving, with a focus on expanding production capacities and enhancing product portfolios. Collaborations between public and private sectors are also on the rise, aiming to improve access to plasma therapies across Europe.

Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is an emerging powerhouse in the plasma fractionation market, holding approximately 20% of the global share. The region is experiencing rapid growth due to increasing healthcare investments, rising awareness of plasma-derived therapies, and a growing population. Countries like China and India are witnessing significant demand, driven by the rising incidence of hemophilia and other blood-related disorders, alongside supportive government initiatives. China is the largest market in the region, with key players like Hualan Biological Engineering leading the charge. India is also making strides, with a focus on expanding its plasma collection and processing capabilities. The competitive landscape is characterized by both local and international players, fostering innovation and improving access to essential therapies across the region.

Middle East and Africa : Untapped Market with Potential

The Middle East and Africa represent an untapped market for plasma fractionation, holding about 5% of the global share. The region is gradually recognizing the importance of plasma-derived therapies, driven by increasing healthcare investments and a rising prevalence of chronic diseases. Regulatory frameworks are evolving, with governments focusing on improving healthcare infrastructure and access to essential treatments, which is expected to catalyze market growth in the coming years. Countries like South Africa and the UAE are leading the way in adopting plasma therapies, with a growing number of healthcare facilities investing in plasma collection and processing. The competitive landscape is still developing, with opportunities for both local and international players to establish a foothold in this emerging market. Strategic partnerships and collaborations are likely to play a crucial role in expanding market presence and improving patient access to therapies.

Key Players and Competitive Insights

The Plasma Fractionation Market has witnessed significant growth over recent years, driven by the increasing demand for plasma-derived therapies and the rising prevalence of various disorders such as hemophilia, immune deficiencies, and certain cancers.
This market is characterized by the presence of numerous key players, each striving to enhance their product offerings and expand their market share.
Competitive insights into this market reveal a landscape where innovation, strategic partnerships, and regulatory considerations play vital roles. Plasma manufacturers are focusing on research and development to improve existing advanced plasma products, while also exploring new therapeutic areas to address unmet medical needs.
Additionally, the blood plasma market is experiencing consolidation through mergers and acquisitions as organizations aim to leverage synergies and streamline their operations.LFB Group has established itself as a prominent player in the Plasma Fractionation Market through its emphasis on high-quality products and patient-centric solutions. The company benefits from its strong research and development capabilities, allowing it to introduce innovative plasma-derived therapies that meet the increasing global healthcare demands.
LFB Group's market presence is bolstered by its commitment to safety and efficacy, which resonates well with healthcare providers and patients alike.
The organization has developed a wide range of immunoglobulin and clotting factor products that cater to various therapeutic needs, making it a trusted name within plasma industries. Its collaborations with academic institutions and healthcare organizations further enhance its competitive position, emphasizing its role as a leader in providing specialized plasma-derived therapies globally.Takeda Pharmaceutical is another key participant in the Plasma Fractionation Market, recognized for its extensive portfolio of biologics and Takeda plasma derived therapies. The company offers a range of products, including immunoglobulins, clotting factors, and other therapeutic proteins, which serve various medical conditions.
Takeda's strength lies in its robust global presence, allowing it to reach a wide patient population and address local healthcare challenges effectively. With a strong focus on research and strategic partnerships, Takeda is actively engaged in mergers and acquisitions to enhance its technological capabilities and expand its product offerings.
These initiatives not only bolster its market position but also promote innovation in plasma fractionation technologies. The company’s commitment to patient access and improving health outcomes further solidifies its standing as a leader in the global blood plasma market, enhancing its competitiveness in this dynamic industry.

Key Companies in the Plasma Fractionation Market include

Industry Developments

Significant news developments in the Plasma Fractionation Market include accelerated growth driven by increasing demand for immunoglobulin therapies and advancements in plasma-derived products. Companies like Grifols and CSL Behring are enhancing their production capabilities through investments in new facilities and technology.

In October 2023, Takeda Pharmaceutical announced plans to expand its manufacturing footprint in response to heightened demand, illustrating the competitive landscape.

Recent mergers and acquisitions have also shaped plasma industries; for instance, in September 2023, ADMA Biologics finalized its acquisition of a specialized plasma collection center to strengthen its supply chain.

Additionally, in December 2022, Octapharma and Hualan Biological Engineering formed a collaborative agreement to enhance production efficiency, indicating strategic alliances within the sector.

Moreover, technological advancements in plasma fractionation processes are improving yield and reducing costs, benefiting plasma manufacturers like Emergent BioSolutions and Biotest AG.

The overall market valuation continues to grow as consumer awareness of plasma-derived therapies rises, with emerging markets contributing to increasing investments. This growth trend emphasizes the importance of operational excellence and innovation in the industry's future endeavors while navigating regulatory landscapes in various global regions.

Future Outlook

Plasma Fractionation Market Future Outlook

The Plasma Fractionation Market is projected to grow at a 6.59% CAGR from 2025 to 2035, driven by increasing demand for immunoglobulins and advancements in fractionation technologies.

New opportunities lie in:

<p>Expansion of contract manufacturing services for biopharmaceutical companies. Development of innovative plasma-derived therapies targeting rare diseases. Investment in automated plasma collection and processing technologies.</p>

By 2035, the Plasma Fractionation Market is expected to achieve substantial growth and innovation.

Market Segmentation

Plasma Fractionation Market End User Outlook

Hospitals
Ambulatory Surgical Centers
Blood Banks
Pharmaceutical Companies

Plasma Fractionation Market Technology Outlook

Centrifugation
Chromatography
Precipitation
Filtration

Plasma Fractionation Market Application Outlook

Neurology
Hematology
General Medicine
Immunology

Plasma Fractionation Market Product Type Outlook

Immunoglobulin
Albumin
Coagulation Factors
Protease Inhibitors

Report Scope

MARKET SIZE 2024	31.82(USD Billion)
MARKET SIZE 2025	33.92(USD Billion)
MARKET SIZE 2035	64.22(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	6.59% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), Octapharma (CH), Kedrion S.p.A. (IT), Biotest AG (DE), LFB Group (FR), Hualan Biological Engineering Inc. (CN)
Segments Covered	Applications, Product Type, End Users, Technology, Regional
Key Market Opportunities	Advancements in immunoglobulin therapies drive growth in the Plasma Fractionation Market.
Key Market Dynamics	Rising demand for immunoglobulins drives innovation and competition in the Plasma Fractionation Market.
Countries Covered	North America, Europe, APAC, South America, MEA